New Risk • Jun 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (kr293.5m market cap, or US$29.5m). Aankondiging • Jun 19
SoftOx Solutions AS announced that it has received NOK 6.029468 million in funding from Long State Investments Limited On June 18, 2026, the SoftOx Solutions AS closed the transaction. Aankondiging • Jun 10
SoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments Limited SoftOx Solutions AS has announced to issue 46 380 523 shares at an issue price of NOK 0.13 per share for gross proceeds of NOK 6,029,467.99 on June 9, 2026. The transaction includes returning investor participation from Long State Investments Limited. Aankondiging • Jun 05
SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical Study SoftOx Solutions AS announced that the first participant has been enrolled in the SIS-02 Phase 1 clinical study in Ireland. The enrollment follows the previously announced approval of the SIS-02 clinical trial application by Ireland’s Health Products Regulatory Authority (HPRA) and marks the formal initiation of the study. The SIS-02 Phase 1 study is designed to evaluate the safety, tolerability, and pulmonary exposure profile of SoftOx Inhalation Solution (“SIS”) following inhaled administration in healthy volunteers and supports the continued development of SIS for defence and biological countermeasure applications. The initiation of SIS-2 represents an important operational milestone for SoftOx and expands the Company’s clinical trial pipeline from one to two ongoing clinical studies. SIS-02 is separate from, and independent of, the Company’s SIS-03 study in chronic lung infections in patients, including cystic fibrosis. Together, the two SIS programs support SoftOx’s strategy to develop SIS as an inhaled anti-infective therapy with potential relevance in both civilian healthcare and defence-related biological preparedness. The SIS-02 program is formally conducted through SoftOx’s wholly owned subsidiary, SoftOx Defense Solutions AS, and is grant-funded through SoftOx’s participation in the COUNTERACT Consortium, which is funded by the European Defence Fund and includes universities, public research institutes, and companies across Europe. The program is also supported by the Norwegian Ministry of Defence. The SIS-02 study is intended to add to the clinical evidence base for SIS and support the planning of subsequent development activities. SoftOx will provide further updates on SIS-02 as the study progresses and when relevant data reviews have been completed. SoftOx Solutions AS is developing SIS, a novel inhaled anti-infective therapy for respiratory infections in the airways and lungs. Delivered by nebulizer, SIS is being developed to address bacterial, viral, and fungal pathogens through local delivery directly at the site of infection, without systemic exposure to the remainder of the human body. Its broad pathogen relevance positions SIS as a distinct therapeutic in respiratory infections. New Risk • Mar 26
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (kr174.4m market cap, or US$18.1m). New Risk • Dec 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr219.9m market cap, or US$21.9m). Aankondiging • Sep 27
SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments Limited On September 26, 2025, SoftOx Solutions AS closed the transaction. Aankondiging • Jun 30
SoftOx Solutions AS Appoints Tore Duvold as New Board Member SoftOx Solutions AS at its Annual General Meeting, announced the election of Dr. Tore Duvold as a new member of the Board of Directors. Dr. Duvold brings over 25 years of experience in the life science sector, including leadership roles in biotech, pharma, and public innovation funding. He currently serves as CEO of the Swedish diagnostics company Spermosens AB and has held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark, Edvince AB, and Coegin Pharma. In addition, he has served on the board of Medicon Valley Alliance and been involved in several board roles. Aankondiging • Dec 19
SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026 SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026. Aankondiging • Sep 13
SoftOx Solutions AS to Appeal Court Ruling in Consultant Bonus Dispute The District Court of Ringerike, Asker, and Bærum has made its ruling in a dispute between SoftOx Solutions AS and a former consultant claiming to have a bonus claim for services rendered in 2022. The district court ruled in favor of the consultant and awarded the consultant approx. NOK 2.5 million plus interest, and NOK 484,000 in compensation including legal costs. The Company believes that the claim has no merits, and the ruling will be appealed. Aankondiging • Sep 12
SoftOx Solutions AS Elects Additional Board Members SoftOx Solutions AS at its ExtraOrdinary General Meeting held on 12 September 2024, elected as additional board member: Christian Vinding Thomsen, Vice Chairman of the Board and Eskil Zapffe, board member with an election term until the annual general meeting in 2025. Aankondiging • May 01
SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million. SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 13,345,951
Price\Range: NOK 0.2
Transaction Features: Rights Offering New Risk • Apr 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 47x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 47x increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$645k). Minor Risks Negative equity (-kr268k). Market cap is less than US$100m (kr156.1m market cap, or US$14.4m). New Risk • Apr 05
New minor risk - Negative shareholders equity The company has negative equity. Total equity: -kr268k This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$650k). Market cap is less than US$10m (kr4.29m market cap, or US$399.5k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Aankondiging • Mar 28
SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million. SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: NOK 0.2
Transaction Features: Rights Offering New Risk • Mar 27
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: kr7.0m (US$649k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$649k). Market cap is less than US$10m (kr8.84m market cap, or US$821.8k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). New Risk • Sep 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (kr51.7m market cap, or US$4.79m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m). Board Change • Mar 10
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Kari Myren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman Melvin Teigen was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Mar 17
Danish Medicines Agency Approves First-In-Human Clinical Study for SoftOx Solutions AS Wound Treatment Agent for Infections in Chronic Wounds, Biofilm Eradicator SoftOx Solutions AS announced that the Danish Medicines Agency (DKMA) has authorised the SBE-01 clinical trial on medicinal products. The authorisation is given pursuant to § 88(1) of the Danish Medicines Act.1. This is the first-in-man (phase I) study with lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. This approval represents an important milestone for SoftOx Solutions AS and is of crucial importance for the further development of an effective infection treatment of problematic wounds, where there is an unmet medical need. It is also an important step forward for the company's collaboration and funding partners, such as University of Copenhagen, Bispebjerg University Hospital, US Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and The Research Council of Norway. The SBE-01 study will commence as soon as permission has also been granted by the relevant Scientific Ethical Committee. SBE-01: EudraCT no. 2021-000314-42. Is New 90 Day High Low • Feb 20
New 90-day low: kr56.50 The company is down 18% from its price of kr68.50 on 20 November 2020. The Norwegian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Aankondiging • Dec 23
SoftOx Solutions AS Announces New Distribution Agreement SoftOx Solutions AS announced new distribution agreement. Distributor Bonaventura Scandza has signed an agreement with NorgesGruppen for the sale of SafeDes alcohol-free hand disinfectant. From February, some of the country's grocery chains will start selling SoftOx SafeDes hand disinfectant under the brand name «Aeris». The agreement with NorgesGruppen includes Meny, Spar, and Bunnpris stores, where 39 Meny stores will include the products in a fixed listing, while partner Bonaventura Scandza will be allowed to sell products to all the other stores locally. Meny has a total of 200 stores, Spar has 295, and Bunnpris has 250. As a result of increased focus on infection prevention and control among consumers, Bonaventura Scandza in collaboration with Aeris AS and SoftOx Solutions AS has created a new category for infection control products under the Aeris brand, which includes hand disinfectants from SoftOx Solutions. These three companies will now together market and sell Aeris's products to the pharmacies and the retail market in the Nordic countries and the UK. Is New 90 Day High Low • Sep 28
New 90-day high: kr81.00 The company is up 9.0% from its price of kr74.50 on 30 June 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.